Patients with a history of Guillain-Barré syndrome appear to have a low risk of recurrence if they are vaccinated with Comirnaty, a study of medical records shows.

Doctors from Maccabi Healthcare Services in Tel Aviv, which serves a quarter of the Israeli population, have reported outcomes for 579 patients with a history of Guillain-Barré syndrome (GBS) who subsequently received the mRNA COVID-19 vaccine as guidelines did not contraindicate it.

In total, 539 of the patients had two vaccine doses and 40 had only one dose, mostly because they had already had COVID-19 and Israeli guidelines specify a single dose in that situation.

Over a median follow-up of 90 days from the second dose, 48 patients were seen in hospital for various reasons but only one patient was diagnosed with recurrent GBS.